2 Reduced MSC-mediated T-cell suppression capacity in patients with atherosclerosis and type 2 diabetes. a MSCs from patients with atherosclerosis (ATH; n = 18; * p = 0.02) have a decreased capacity to suppress CD4 + T-cell proliferation at 1:8 MSC:CD4 + T cell ratio compared to age-matched controls without atherosclerosis (non-ATH, n = 9). b MSCs from patients with ATH (n = 12) and type 2 diabetes mellitus (T2DM) (n = 12) have impaired suppressive capacity compared to age-matched ATH controls (* p = 0.04). c MSC function is compromised in age-matched patients with chronic inflammatory diseases (non-ATH < ATH < ATH+T2DM; n = 7 per group; * p = 0.02, ** p = 0.002) The PRECISE trial demonstrated the feasibility, safety and potential therapeutic benefit of the transendocardial administration of autologous adipose-derived MSCs in no-option patients with ischemic cardiomyopathy [ 7 ].
Source: wiktionary